Recipharm and Roche sign agreement to manufacture solid dose products


Swedish pharmaceutical company Recipharm has signed a long-term manufacturing agreement with Roche to produce a wide range of solid dose products.

Under the deal, the company will also purchase a manufacturing facility from Roche.

Located in Leganés, Spain, the well-equipped manufacturing factory currently employs approximately 200 people and develops solid dose products.

The facility is licensed to supply products to more than 95 countries worldwide.

The long-term manufacturing agreement will add Recipharm’s annual sales of approximately €35m with the company’s overall target.

"We are continuing to gain momentum in the contract development and manufacturing organisation (CDMO) market through our various profitable growth initiatives."

Recipharm chief executive officer Thomas Eldered said: “We are continuing to gain momentum in the contract development and manufacturing organisation (CDMO) market through our various profitable growth initiatives.

“I am therefore delighted to announce this long-term agreement with Roche. It has become clear during our interactions with Roche that we are closely aligned in our ways of doing business, and we look forward to developing this relationship further by providing high-quality, reliable supplies from Leganés in future.

“In addition, we see a highly interesting business development opportunity to add new customers.”

The acquisition of the solid dose products factory and the performance of the manufacturing agreement will be organised in a wholly owned subsidiary of Recipharm.

Closing of the transaction and initiation of the product supply is expected by the end of this year.